Mirabegron (trade name Myrbetriq meer-bet-trick in the US and Betmiga in Europe) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012.
Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.
- ProName: Mirabegron
- CasNo: 223673-61-8
- Molecular Formula: C21H24N4O2S
- Appearance: light yellow solid
- DeliveryTime: 3 months
- PackAge: 100g,500g,1kg,25kg
- Port: shang hai
- ProductionCapacity: 1000 Metric Ton/Month
- Purity: 98%
- Transportation: shipping
- LimitNum: 100 Gram
No comments:
Post a Comment